Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | UCART22 |
| Trade Name | |
| Synonyms | UCART-22|UCART 22 |
| Drug Descriptions |
UCART22 is a preparation of allogeneic T-cells expressing a chimeric antigen receptor (CAR) that targets CD22, potentially resulting in decreased tumor growth (Cancer Res July 1 2017 (77) (13 Supplement) 3763). |
| DrugClasses | CD22 Immune Cell Therapy 13 |
| CAS Registry Number | NA |
| NCIT ID | C165696 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Alemtuzumab + Cyclophosphamide + Fludarabine + UCART22 | Alemtuzumab Cyclophosphamide Fludarabine UCART22 | 0 | 0 |
| Cyclophosphamide + Fludarabine + UCART22 | Cyclophosphamide Fludarabine UCART22 | 0 | 0 |
| UCART22 | UCART22 | 0 | 1 |